Isoliquiritigenin是一种来源于甘草的黄酮类化合物，Isoliquiritigenin可激活Nrf2通路以减少氧化应激和炎症，同时通过诱导细胞凋亡来抑制癌症进展。
Cas No.:961-29-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Isoliquiritigenin is a flavonoid compound derived from licorice. Isoliquiritigenin can activate the Nrf2 pathway to reduce oxidative stress and inflammation, while also inhibiting cancer progression by inducing apoptosis[1-2]. Isoliquiritigenin can also inhibit the activity of aldose reductase, neutralize free radicals to reduce oxidative damage, and is used in research related to the nervous system, antiviral, antitumor, and other areas[3-4].
In vitro, treatment of SK-MEL-28 human melanoma cells with Isoliquiritigenin (1–50µM) for 24–72 hours, Isoliquiritigenin significantly induced apoptosis and reduced cell viability by triggering the mitochondrial pathway (activating caspase-9/-7/-3, PARP cleavage, regulating the Bax/Bcl-2 balance, promoting cytochrome C release) and inhibiting the ROS-mediated p38/mTOR/STAT3 signaling pathway[5]. Treatment of NOZ and SGC-996 human gallbladder cancer cells with Isoliquiritigenin (20–100µM) for 24–72 hours, Isoliquiritigenin induced ferroptosis and inhibited cell proliferation by activating the p62-Keap1-Nrf2-HMOX1 axis, downregulating GPX4 expression, leading to iron accumulation, lipid peroxidation, and disruption of the GSH/GSSG ratio[6].
In vivo, intragastric administration of Isoliquiritigenin (5–20mg/kg/day) to ICR mice with cerebral ischemia-reperfusion injury (pretreated for 7 days, assessed 24 hours post-surgery), Isoliquiritigenin significantly reduced cerebral infarct volume and neurological deficits, and ameliorated oxidative stress and mitochondrial dysfunction by activating the Nrf2 pathway[7]. Intragastric administration of Isoliquiritigenin (20mg/kg/day) to high-fat diet-induced obese C57BL/6 mice (continued for 8 weeks), Isoliquiritigenin significantly reduced weight gain and white adipose tissue deposition, and activated the expression of thermogenesis-related genes in brown adipose tissue[8].
References:
[1] Chen Z, Ding W, Yang X, et al. Isoliquiritigenin, a potential therapeutic agent for treatment of inflammation-associated diseases. J Ethnopharmacol. 2024 Jan 10;318(Pt B):117059.
[2] Qiu M, Ma K, Zhang J, et al. Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications. Front Pharmacol. 2024 Oct 9;15:1395735.
[3] Wang KL, Yu YC, Hsia SM. Perspectives on the Role of Isoliquiritigenin in Cancer. Cancers (Basel). 2021 Jan 1;13(1):115.
[4] Zhang Z, Yung KK, Ko JK. Therapeutic Intervention in Cancer by Isoliquiritigenin from Licorice: A Natural Antioxidant and Redox Regulator. Antioxidants (Basel). 2022 Jul 11;11(7):1349.
[5] Kwon MJ, Raut PK, Jang JH, et al. Isoliquiritigenin Induces Apoptosis via ROS-Mediated Inhibition of p38/mTOR/STAT3 Pathway in Human Melanoma Cells. Biomol Ther (Seoul). 2025 Mar 1;33(2):378-387.
[6] Wang Z, Li W, Wang X, et al. Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells. Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220.
[7] Lan X, Wang Q, Liu Y, et al. Isoliquiritigenin alleviates cerebral ischemia-reperfusion injury by reducing oxidative stress and ameliorating mitochondrial dysfunction via activating the Nrf2 pathway. Redox Biol. 2024 Nov;77:103406.
[8] Zhao L, Li M, Zhu Q, et al. Isoliquiritigenin Ameliorates High-Fat Diet-Induced Obesity in Mice by Activating Brown Adipose Tissue. Int J Mol Sci. 2025 Feb 14;26(4):1616.
Isoliquiritigenin是一种来源于甘草的黄酮类化合物，Isoliquiritigenin可激活Nrf2通路以减少氧化应激和炎症，同时通过诱导细胞凋亡来抑制癌症进展[1-2]。Isoliquiritigenin还可以抑制aldose reductase的活性，可中和自由基来减少氧化损伤，Isoliquiritigenin被用于神经系统、抗病毒、抗肿瘤等相关研究[3-4]。
在体外，Isoliquiritigenin（1–50μM）处理SK-MEL-28人黑色素瘤细胞24–72小时，Isoliquiritigenin通过诱导线粒体途径（激活caspase-9/-7/-3、PARP裂解，调控Bax/Bcl-2平衡，促进细胞色素C释放）和ROS介导的p38/mTOR/STAT3信号通路抑制，显著诱导细胞凋亡并降低细胞存活率[5]。Isoliquiritigenin（20–100μM）处理NOZ和SGC-996人胆囊癌细胞24–72小时，Isoliquiritigenin通过激活p62-Keap1-Nrf2-HMOX1轴、下调GPX4表达，引起铁离子积累、脂质过氧化和GSH/GSSG比率失衡，从而诱导铁死亡并抑制细胞增殖[6]。
在体内，Isoliquiritigenin（5–20mg/kg/day）灌胃处理脑缺血再灌注损伤模型ICR小鼠（预处理7天，术后24小时评估），Isoliquiritigenin显著减轻脑梗死体积和神经功能缺损，并通过激活Nrf2通路改善氧化应激和线粒体功能障碍[7]。Isoliquiritigenin（20mg/kg/day）灌胃处理高脂饮食诱导的肥胖C57BL/6小鼠（持续8周），Isoliquiritigenin显著降低体重增长和白色脂肪组织沉积，并激活棕色脂肪组织产热相关基因表达[8]。
| Cell experiment [1]: | |
Cell lines | SK-MEL-28 cells (human melanoma cell line) |
Preparation Method | SK-MEL-28 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100U/mL penicillin G and 100mg/mL streptomycin) at 37°C in a humidified incubator containing 5% CO₂. Cells were treated with Isoliquiritigenin at various concentrations (1, 25, and 50µM) for different durations (24, 48, and 72 hours). |
Reaction Conditions | 1–50μM; 24–72 hours |
Applications | Isoliquiritigenin treatment significantly reduced SK-MEL-28 cell viability in a concentration- and time-dependent manner, Isoliquiritigenin induced apoptosis in SK-MEL-28 cells, including caspase-9, -7, -3, and PARP. Isoliquiritigenin promoted mitochondrial pathway-mediated apoptosis, and stimulating the release of cytochrome C from the mitochondria into the cytosol. |
| Animal experiment [2]: | |
Animal models | ICR mice |
Preparation Method | Mice were pretreated with Isoliquiritigenin or vehicle (0.5% CMC-Na solution) by intragastric administration once a day for seven consecutive days. Subsequently, cerebral ischemia-reperfusion injury (CIRI) was induced by subjecting the mice to 2 hours of left middle cerebral artery occlusion (MCAO) followed by 24 hours of reperfusion. Mice were sacrificed after the reperfusion period for analysis. |
Dosage form | 5, 10, and 20mg/kg; i.g.; Once daily for 7 days. |
Applications | Isoliquiritigenin pretreatment significantly alleviated MCAO-induced cerebral infarction in a dose-dependent manner. The 20mg/kg dose was particularly effective, reduced the infarct volume to a level comparable to the positive control drug, Nimodipine. Isoliquiritigenin administration alleviated histopathological damage in the ischemic cerebral cortex and hippocampal regions. Isoliquiritigenin reduced neuronal loss, disordered arrangement, karyopyknosis, and interstitial swelling, while increasing the integrity of neurons and Nissl bodies. |
References: | |
| Cas No. | 961-29-5 | SDF | |
| 别名 | 异甘草素; GU17; ISL; Isoliquiritigen; SJ000286237 | ||
| 化学名 | (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one | ||
| Canonical SMILES | C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O | ||
| 分子式 | C15H12O4 | 分子量 | 256.25 |
| 溶解度 | ≥ 12.4mg/mL in DMSO | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9024 mL | 19.5122 mL | 39.0244 mL |
| 5 mM | 780.5 μL | 3.9024 mL | 7.8049 mL |
| 10 mM | 390.2 μL | 1.9512 mL | 3.9024 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet